These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20585111)

  • 1. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.
    Fridell RA; Qiu D; Wang C; Valera L; Gao M
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3641-50. PubMed ID: 20585111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
    Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
    Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
    Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
    Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
    Dvory-Sobol H; Han B; Lu J; Yu M; Beran RK; Cheng G; Martin R; Svarovskaia E; Mo H
    J Viral Hepat; 2019 Aug; 26(8):991-1001. PubMed ID: 31009123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank.
    Kliemann DA; Tovo CV; Gorini da Veiga AB; Machado AL; West J
    PLoS One; 2016; 11(8):e0159924. PubMed ID: 27504952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus.
    Zhou S; Williford SE; McGivern DR; Burch CL; Hu F; Benzine T; Ingravallo P; Asante-Appiah E; Howe AYM; Swanstrom R; Lemon SM
    Antiviral Res; 2018 Oct; 158():45-51. PubMed ID: 30081054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus.
    Peres-da-Silva A; de Almeida AJ; Lampe E
    J Antimicrob Chemother; 2015 Mar; 70(3):726-30. PubMed ID: 25414201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.
    Fridell RA; Qiu D; Valera L; Wang C; Rose RE; Gao M
    J Virol; 2011 Jul; 85(14):7312-20. PubMed ID: 21593143
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
    Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.
    Kliemann DA; Tovo CV; da Veiga AB; de Mattos AA; Wood C
    World J Gastroenterol; 2016 Oct; 22(40):8910-8917. PubMed ID: 27833382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
    Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.
    Liu M; Tuttle M; Gao M; Lemm JA
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7416-23. PubMed ID: 25267677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
    Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
    Liu R; Curry S; McMonagle P; Yeh WW; Ludmerer SW; Jumes PA; Marshall WL; Kong S; Ingravallo P; Black S; Pak I; DiNubile MJ; Howe AY
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6922-9. PubMed ID: 26303801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
    Gao M; Nettles RE; Belema M; Snyder LB; Nguyen VN; Fridell RA; Serrano-Wu MH; Langley DR; Sun JH; O'Boyle DR; Lemm JA; Wang C; Knipe JO; Chien C; Colonno RJ; Grasela DM; Meanwell NA; Hamann LG
    Nature; 2010 May; 465(7294):96-100. PubMed ID: 20410884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.